Introduction
Lacosamide (LCM) is an AED initially approved for the adjunctive treatment of partial-onset seizures in adult patients. Three double-blind, placebo-controlled trials [1] [2] [3] and two longterm follow-up studies [4, 5] have established the clinical efficacy and safety of the oral formulation of LCM in patients with pharmacoresistant partial epilepsy. In 2014, a FDA license extension allowed LCM to be used as monotherapy for the treatment of partial-onset seizures in patients 17 years of age and older in the USA while in the European Union LCM has not yet received EMA approval for its use as monotherapy. A randomized, historical-controlled, monotherapy conversion trial conducted in the USA has demonstrated that LCM 400 mg/daily is effective for the treatment of adult patients with focal epilepsy with a favorable safety profile [6] . In Europe, a multicentre, randomized monotherapy study comparing LCM with sustained release CBZ in patients with partial-onset seizures is currently underway. So far, experience with LCM monotherapy in a real-life clinical setting is sparse and limited to reports of a few patients with conversion to monotherapy [4, 7, 8] . In the largest and more recent of these series, Purpose: The goal of this study is to report the efficacy and tolerability of lacosamide (LCM) monotherapy, as first-line and conversion regimens, in the treatment of patients with partial-onset seizures. Methods: We retrospectively reviewed the charts of patients with focal epilepsy on LCM monotherapy from six centers in Spain. Efficacy and tolerability were evaluated in the overall group and in subgroups of patients who were naive to antiepileptic drug (AED) therapy (Group 1) and those who had previously been treated with AEDs (Group 2). Results: Sixty-six patients were identified including 18 patients in Group 1 and 48 patients in Group 2. Patients were followed up for 0.5-54 months in monotherapy (mean 15.5 months). Forty-two (63.6%) patients remained seizure-free during all the follow-up. At 6 and 12 months, seizure-free rates were 77.6% and 72.3%, respectively. The drug was withdrawn in 10 (15%) patients (3 side effects, 6 lack of efficacy, 1 other reason). Fifteen (22.7%) patients reported mild to moderate side effects with the use of LCM. No differences were found between Groups 1 and 2 regarding efficacy outcomes or tolerability issues. Conclusions: In our series more than two-thirds of the patients remained seizure-free on LCM monotherapy. Side effects were generally mild and led to discontinuation in only 3/66 (4.5%) patients. Our experience suggests that LCM monotherapy, either as first-line or after conversion, may be a valuable option for patients with focal epilepsy.
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19 of 22 patients (86.4%) who were converted to monotherapy remained seizure free at 6 and 12 months follow-up [8] . However, no efficacy and tolerability data on the use of LCM as first-line monotherapy are available. The aim of the present study is to explore the clinical outcome in patients on LCM monotherapy reached after initial prescription or after conversion to monotherapy in daily clinical practice.
Methods
All patients with partial onset-seizures from six hospitals in Spain who had been treated with at least one dose of LCM monotherapy since the introduction of the drug in September 2009 until May 2014 were identified. Charts were reviewed for patient demographic and clinical data including age at seizure onset, maintenance dose, duration of treatment and adverse events. For the purposes of this analysis patients were divided into two groups: those with recently diagnosed epilepsy for whom LCM was their first AED (Group 1) and those who reached LCM monotherapy after discontinuing other AEDs (Group 2). In the latter group we also recorded the reason for introducing LCM (seizure control or intolerance to other AEDs), and previous and concomitant antiepileptic drug therapy. After reviewing clinical data records, patients with an inaccurate diagnosis of epilepsy, treatment noncompliance and/or unreliable seizure frequency account were excluded from the analysis.
According to the participating physicians criteria, a daily dose of 50 or 100 mg of LCM was prescribed initially and titrated to an optimal maintenance dose for each patient depending on efficacy and tolerability.
Efficacy was evaluated by analyzing seizure-free rates and mean seizure frequency reduction during the complete follow-up and during the first 6 and 12 months after reaching the fixed maintenance dose. Seizure freedom was defined as no seizures on LCM monotherapy during the evaluated study period (complete follow-up or 6 and 12 months after reaching the maintenance dose).
Frequency and types of side effects related to the use of LCM were recorded. We also studied the one-year retention rate.
Statistical analysis
Data were analyzed using descriptive statistics. The Chi-square test (or Fisher's exact test if the expected frequency was lower than five in at least 20% of the cells) was used to compare subgroups with respect to efficacy, percentage of patients with AEs and discontinuation for AEs. The Mann-Whitney U test was used to analyze quantitative variables (time since epilepsy onset and number of seizures per month). Student's t-test was used to compare subgroups with respect to LCM dose changes.
Statistical significance was defined at p < 0.05. All statistical analysis was performed using SPSS version 19.0 (IBM Corporation, Armonk, NY, US).
Results

Patient population
We identified 66 patients with partial epilepsy who had received at least one dose of LCM monotherapy, 18 (27.3%) patients in Group 1 and 48 (72.7%) patients in Group 2. Only 2/66 patients had learning difficulties. Group 2 included 9 patients (13.6%) directly switched to LCM in the epilepsy monitoring unit or the emergency room and 39 (59.1%) patients slowly converted to LCM monotherapy. Mean number of prior AEDs in Group 2 was 2.41 (range 1-9, median 1) and 50% of the patients had previously tried 2 or more AEDs. Reasons for introduction of LCM in patients in Group 2 were seizure control in 29 (60.4%), tolerability problems in 10 (20.8%), both in 6 (12.5%), and treatment with an AED not considered to be appropriate for the type of epilepsy in 3 patients. The demographic and clinical characteristics of the patients are presented in Table 1 .
Median monthly seizure frequency in the 12-month period prior to LCM monotherapy was 0.7 (SD 9.4; range 0-60) and mean follow-up in monotherapy was 15.5 months (range 0.5-54 months). Four patients had been seizure-free for at least one year previous to starting LCM. At the end of the study, 43 (65%) patients had received LCM monotherapy for more than 12 months. Overall, the mean maintenance dose of LCM in monotherapy was 252.7 mg/day (range 100-600). The dose of LCM was significantly higher in patients from Group 2 than in patients from Group 1 (270.8 vs. 204.2 mg; p = 0.003).
Efficacy
Forty-two (63.6%) patients remained seizure-free in monotherapy during all the follow-up. A proportion of patients achieved seizure-freedom after reaching the maintenance dose following dosage adjustments: the seizure-free rates at 6 and 12 months on the maintenance dose were 77.6% and 72.3%, respectively.
Mean seizure frequency reduction for the overall group was 74.8% at 6 months and 75.6% at 12 months (p < 0.001). Ten (15%) patients discontinued treatment with LCM monotherapy (6 due to lack of efficacy, 3 due to side effects and 1 due to personal preference). The one-year retention rate was 89.4% [IC95 (76.9-96.5%)].
Naïve vs. non-naïve treatment groups
Seizure-free rates were 72.2% (13/18) for Group 1 and 60.4% (29/48) for Group 2 for the complete follow-up period (p = 0.375). Neither seizure-free rates (Fig. 1 ) nor seizure frequency reduction (Table 2 ) were found to be statistically different between the two groups at 6 and 12 months. One-year retention rates were 91.7% for Group 1 and 88.6% for Group 2 (p = 1.00).
Patients with previous lack of seizure control
In 35 patients from Group 2, LCM was started because of uncontrolled seizures despite previous treatment with at least one AED. Mean number of previous AEDs was 2.2 (range 1-9) and 51.4% of patients had been treated with 2 or more drugs. Median monthly seizure frequency in this group was 1 (range 0.3-60) and mean follow-up 16.9 months (range 0.5-54). In total, 54.3% (19/35) remained seizure-free since the onset of LCM monotherapy. At 6 and 12 months seizure-free rates were 66.7% (20/30) and 65.4% (17/26), respectively, and significant reductions in mean seizure frequency were recorded (80.1% and 80.2%; p < 0.001). The retention rate at 12 months was 84.2% [IC95 (65.1-95.6%)]. In total 8 withdrawals were recorded, mainly due to lack of efficacy (6/35; 17.1%).
Tolerability
Fifteen of 66 patients (22.7%) reported mild to moderate side effects (Table 3) ; the most common side effects were somnolence/ fatigue (7.5% of patients) and dizziness (6.1% of patients). Three patients (4.5%) discontinued treatment due to adverse events (intense fatigue = 1, dizziness = 1, pruritus and insomnia = 1), two of them in the first month of treatment. No differences were observed between Groups 1 and 2 regarding the type of side effect or rate of patients suffering side effects (22.9% vs. 22.7%; p = 1.00).
Tolerability in patients with side effects with previous AEDs
LCM was started in 16 patients because of tolerability problems with a previous AED. Mean number of previous AEDs in this group was 2.4 (range 1-9) with 56.2% of the patients having tried at least 2 AEDs. Mean follow-up was 16.7 months (range 0.5-36).
Side effects related to LCM therapy were recorded in only 3 patients (18.8%) and led to discontinuation in 1 patient (fatigue).
Discussion
This study investigates a series of patients with partial-onset seizures on LCM monotherapy as first-line or conversion regimen in clinical practice. Overall, about two-thirds of the 66 patients included in this study remained seizure-free during the complete follow-up and a higher percentage achieved seizure-freedom after reaching a maintenance dose, both at 6 and 12 months, suggesting that some patients benefit from additional up-titration of the drug and that the efficacy is maintained over time.
Direct comparisons with the few other published studies investigating the use of LCM as monotherapy are not feasible due to differences in patient populations and methodologies. As an example there is a remarkable difference between our results and those reported by Wechsler et al. In their LCM monotherapy conversion clinical trial during the 10-week monotherapy phase, only 12.9% and 14.4% of the patients receiving LCM 300 or 400 mg/ day remained seizure-free [6] . This difference can be explained at least in part by the characteristics of the population included in the trial. Inclusion criteria included a minimum of 2 seizures per 28 days during the 8-week baseline period. Additionally mean time since first diagnosis was 17.1 years and 45.4% of the patients had tried 3 or more antiepileptic drugs. These patients might not be considered as eligible for monotherapy in an everyday clinical setting and, as a consequence, results may not reflect the efficacy profile of the drug in the early stages of epilepsy. In contrast, Villanueva et al. reported seizure-free rates as high as 86.4% and 86.4% at 6 and 12 months in 22 patients who were successfully converted to LCM monotherapy after having failed to control seizures with a first or second AED [8] . Among other factors, Fig. 1 . Percentage of patients with LCM as initial monotherapy (Group 1) or switched (Group 2), who remained seizure-free since the onset of LCM monotherapy (complete follow-up) and at 6 and 12 months after reaching a maintenance dose following dosage adjustments. Values as presented as mean AE SD. a p-value for comparison between groups. b p-value for changes vs. baseline.
Table 3
Side effects associated with LCM monotherapy.
Side effect differences in the definition of seizure-freedom (e.g. no seizures for the last 6 months at the 12-month visit in the study by Villanueva et al.) may significantly account for the lower seizure-free rate found in the present study in the subgroup of 35 patients in whom LCM was added because of lack of seizure control with previous AEDs (66.7% and 65.4% at 6 and 12 months). Independently of the mentioned differences between theses studies, altogether these data suggest that better results in terms of efficacy are obtained when LCM monotherapy is used in a less refractory setting [8] .
We did not find significant differences in terms of efficacy between naive-treatment patients and those previously exposed to other AEDs although seizure-free rates were numerically higher in patients with recently diagnosed epilepsy. Significant lower doses of LCM in Group 1 are likely to be inferred as it includes an easier to treat population. Given the pragmatic approach used in this study, differences in LCM doses may also reflect physician's preferences such as the use of higher initial drug doses before switching to monotherapy in patients who have failed a previous AED. Aside from the small sample size precluding statistical significance, lack of differences may also be related to the clinical characteristics of the patients included in the latter group. The majority (70.8%) of these patients had failed a maximum of only two previous drugs, including a small percentage of patients with tolerability problems and seizurefree before LCM had been added. Actually, in our routine clinical practice, monotherapy is usually not attempted in patients with more refractory epilepsy. Accordingly, in an audit of levetiracetam (LEV) monotherapy, Stephen et al. [9] found that seizure freedom was more likely in those patients who switched after failing their 1st or 2nd AED compared to later in the treatment schedule (60.9 vs. 13.3%), and similar to those with LEV as a first monotherapy (54.4%).
In this study LCM was generally well tolerated and associated with only mild to moderate side effects, even in patients who had failed previous AEDs because of tolerability problems. Only a small proportion of patients (4.5%) discontinued treatment with LCM because of side effects. Postmarketing studies investigating adjunctive LCM reported much higher rates of AE ranging from 33 to 61% [4, 10, 11] and discontinuation rates from 9 to 22% [7, 10, 11] . Monotherapy with a single AED has been related with a lower risk of toxicity and a reduction in the number of adverse events [12] . Interestingly, we did not find significant differences in the rate or profile of AEs between patients naive to AED therapy and those converted to monotherapy. This could be explained by the initial low doses and flexible titration schedule employed in the present study, which may have improved tolerability even in patients already established in AED therapy. In the Wechsler et al. study up to 84.5% of the patients reported side effects, a safety profile similar to that observed in LCM add-on regulatory trials. The highest incidence of AEs occurred during the titration phase while patients were still receiving background AEDs. However, not only polytherapy but also the higher initial LCM doses of 200 mg/day and fixed titration to the randomized dose in this study can explain the high incidence of AE [6] . In our series, and in agreement with previous studies, the commonest side effects were somnolence/fatigue, dizziness and headache.
The present study is limited by its retrospective nature and, as already mentioned, the small sample size of the subgroups that may preclude finding differences of efficacy and tolerability between naive-treatment patients and those previously exposed to other AEDs. However, the value of our study includes the existence of long-term follow-up data and a real-life picture of the performance of LCM monotherapy in routine clinical practice, including its use as a first-line regimen.
Conclusions
In this series, the outcome of patients treated with LCM monotherapy is encouraging. More than two-thirds of the patients remained seizure-free since the beginning of treatment and an additional proportion of patients achieved long-term seizure freedom following dosage adjustments. Tolerability was good and only a small proportion of patients discontinued LCM because of tolerability problems. Our experience suggests that LCM monotherapy, whether as first-line or after conversion, may be a valuable treatment option for patients with focal epilepsy.
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